Dynamics of SARS‐CoV‐2 Spike Receptor‐Binding Domain‐Targeted Specific Peripheral Memory B Cells in Patients With End‐Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID‐19 Vaccination DOI

Ángela Sánchez‐Simarro,

Nayara Panizo, Estela Giménez

и другие.

Journal of Medical Virology, Год журнала: 2025, Номер 97(5)

Опубликована: Май 1, 2025

Memory B cells (MBCs) are responsible for maintaining long-lasting functional B-cell immune responses. Little is known about the kinetics of peripheral blood (PB) SARS-CoV-2 vaccine-induced MBCs in end-stage chronic kidney disease (CKD) patients undergoing replacement therapies. We investigated this issue prospective, observational cohort study including 27 (9 females and 18 males; median age, 68.4 years, range 48-82) comprising 20 hemodialysis 7 Kidney transplant recipients. SARS-CoV-2-Receptor-Binding Domain (RBD)-targeted PB-MBCs were enumerated by flow cytometry using a tetramer-binding assay after second COVID-19 mRNA vaccine dose (Post-2D), before (Pre-3D), first booster (Post-3D). Commercially available electrochemiluminescent immunoassays used to measure total anti-RBD antibodies targeting an IgG against S trimeric protein. Overall, 18/27 (66.6%) exhibited detectable RBD-MBC responses at Post-2D, 12/27 (44.4%) Pre-3D, 16/27 (59.2%) Post-3D. levels dropped non-significantly between post-2D Pre-3D (p = 0.38). A nonsignificant increase RBD-MBCs was noticed post-3D 0.65). both antibody specificities displayed same dynamics but drop anti-trimeric spike Post-2D increases statistically significant < 0.001). No correlation (rho 0.05; p 0.64) observed RBD counts. The protein counts very weak (rho, 0.18; 0.11). In summary, waning less marked than that anti-S antibodies.

Язык: Английский

Dynamics of SARS‐CoV‐2 Spike Receptor‐Binding Domain‐Targeted Specific Peripheral Memory B Cells in Patients With End‐Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID‐19 Vaccination DOI

Ángela Sánchez‐Simarro,

Nayara Panizo, Estela Giménez

и другие.

Journal of Medical Virology, Год журнала: 2025, Номер 97(5)

Опубликована: Май 1, 2025

Memory B cells (MBCs) are responsible for maintaining long-lasting functional B-cell immune responses. Little is known about the kinetics of peripheral blood (PB) SARS-CoV-2 vaccine-induced MBCs in end-stage chronic kidney disease (CKD) patients undergoing replacement therapies. We investigated this issue prospective, observational cohort study including 27 (9 females and 18 males; median age, 68.4 years, range 48-82) comprising 20 hemodialysis 7 Kidney transplant recipients. SARS-CoV-2-Receptor-Binding Domain (RBD)-targeted PB-MBCs were enumerated by flow cytometry using a tetramer-binding assay after second COVID-19 mRNA vaccine dose (Post-2D), before (Pre-3D), first booster (Post-3D). Commercially available electrochemiluminescent immunoassays used to measure total anti-RBD antibodies targeting an IgG against S trimeric protein. Overall, 18/27 (66.6%) exhibited detectable RBD-MBC responses at Post-2D, 12/27 (44.4%) Pre-3D, 16/27 (59.2%) Post-3D. levels dropped non-significantly between post-2D Pre-3D (p = 0.38). A nonsignificant increase RBD-MBCs was noticed post-3D 0.65). both antibody specificities displayed same dynamics but drop anti-trimeric spike Post-2D increases statistically significant < 0.001). No correlation (rho 0.05; p 0.64) observed RBD counts. The protein counts very weak (rho, 0.18; 0.11). In summary, waning less marked than that anti-S antibodies.

Язык: Английский

Процитировано

0